2012
Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or Diabetes
Marso SP, Mercado N, Maehara A, Weisz G, Mintz GS, McPherson J, Schiele F, Dudek D, Fahy M, Xu K, Lansky A, Templin B, Zhang Z, de Bruyne B, Serruys PW, Stone GW. Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or Diabetes. JACC Cardiovascular Imaging 2012, 5: s42-s52. PMID: 22421230, DOI: 10.1016/j.jcmg.2012.01.008.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAngina, UnstableAngioplasty, Balloon, CoronaryChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary StenosisDiabetes MellitusEuropeFemaleHeart ArrestHumansKaplan-Meier EstimateMaleMetabolic SyndromeMiddle AgedMultivariate AnalysisMyocardial InfarctionNecrosisPlaque, AtheroscleroticPredictive Value of TestsProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTomography, X-Ray ComputedTreatment OutcomeUltrasonography, InterventionalUnited StatesVascular CalcificationConceptsMajor adverse cardiac eventsGreater necrotic coreUntreated nonculprit lesionsAcute coronary syndromeMet SynNonculprit lesionsPercutaneous coronary interventionSYN patientsNecrotic coreMACE rateMetabolic syndromePlaque burdenFuture major adverse cardiac eventsSubsequent major adverse cardiac eventsAcute coronary syndrome patientsSuccessful percutaneous coronary interventionGreater plaque burdenAdverse cardiac eventsCoronary syndrome patientsHigh-risk groupQuantitative coronary angiographySmaller lumen areaACS patientsCoronary syndromeACS population
2011
Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials
Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW. Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC Cardiovascular Interventions 2011, 4: 1209-1215. PMID: 22115661, DOI: 10.1016/j.jcin.2011.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsChi-Square DistributionCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSeverity of Illness IndexSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsReference vessel diameterEverolimus-eluting stentsPercutaneous coronary interventionLong lesionsGroup BLesion lengthMACE rateCoronary interventionSmall vesselsGroup AStent typeShort lesionsAdverse cardiac eventsHigh-risk patientsPatient-level dataLarge vesselsLower ratesCOMPARE trialLesion revascularizationEfficacy outcomesAdverse eventsCardiac eventsIndependent predictors
2005
Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction
Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. Circulation 2005, 111: 1611-1618. PMID: 15811868, DOI: 10.1161/01.cir.0000160362.55803.40.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionPrimary stentingAddition of abciximabBody surface areaCADILLAC trialMyocardial infarctionRisk factorsFemale genderIschemic target vessel revascularizationLower body surface areaMajor adverse cardiac eventsOverall adverse outcomesTIMI grade 3Adverse cardiac eventsTarget vessel revascularizationClinical risk factorsComorbid risk factorsInterventional treatment strategiesImportant independent determinantHigh mortality rateMACE ratePrimary angioplastyCardiac eventsSymptom onsetIndependent predictors
2002
Device selection in the treatment of in-stent restenosis with and without radiation (from the Gamma Radiation Trials)
Ajani AE, Waksman R, Zimarino M, Kim H, Pichard AD, Satler LF, Kent KM, White RL, Pinnow E, Mehran R, Lansky A, Lindsay J. Device selection in the treatment of in-stent restenosis with and without radiation (from the Gamma Radiation Trials). The American Journal Of Cardiology 2002, 89: 137-144. PMID: 11792331, DOI: 10.1016/s0002-9149(01)02189-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceAngioplastyAngioplasty, Balloon, CoronaryChi-Square DistributionCoronary DiseaseDose-Response Relationship, RadiationFemaleHumansIridium RadioisotopesLogistic ModelsMaleMiddle AgedProspective StudiesRisk FactorsSecondary PreventionStentsTreatment OutcomeVascular PatencyConceptsExcimer laser coronary angioplastyMajor adverse coronary eventsAdditional stent implantationTreatment of ISRRecurrence rateCoronary angioplastyRotational atherectomyStent implantationStent restenosisBalloon percutaneous transluminal coronary angioplastyPercutaneous transluminal coronary angioplastyIntracoronary gamma radiationLate clinical outcomesAdverse coronary eventsOverall recurrence rateTransluminal coronary angioplastyLaser coronary angioplastyHigh recurrence rateUse of stentingDevice selectionAngiographic characteristicsMACE ratePlacebo groupPlacebo therapyCoronary events